Loading…
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-43M | $-15M | $-33M | -25.0% | - | - |
| 2024 | $0M | $-27M | $-62M | $-25M | -191.3% | - | - |
| 2023 | $0M | $-23M | $-27M | $-24M | -69.9% | - | - |
| 2022 | $0M | $-32M | $-41M | $-27M | -73.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 32.56 | 23.41 | 27.55 | 42.97 |
| Operating Income | -32.56 | -23.41 | -27.55 | -42.97 |
| EBITDA | -32.20 | -23.26 | -27.46 | -42.87 |
| EBIT | -32.56 | -23.41 | -27.55 | -42.97 |
| Pretax Income | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income Common Stockholders | -41.31 | -27.03 | -62.29 | -15.28 |
| Total Expenses | 32.56 | 23.41 | 27.55 | 42.97 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 0.65 | 1.58 | 1.82 | 2.50 |
| Research And Development | 24.47 | 16.53 | 19.39 | 33.72 |
| Selling General And Administration | 8.10 | 6.88 | 8.16 | 9.25 |
| Normalized EBITDA | -32.22 | -23.26 | 5.91 | -70.01 |
| Normalized Income | -41.33 | -27.03 | -28.92 | -42.42 |
| Basic EPS | -0.89 | -0.56 | -1.02 | 0 |
| Diluted EPS | -0.89 | -0.56 | -1.02 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.02 | 0 | -33.37 | 27.14 |
| Total Unusual Items Excluding Goodwill | 0.02 | 0 | -33.37 | 27.14 |
| Net Income From Continuing Operation Net Minority Interest | -41.31 | -27.03 | -62.29 | -15.28 |
| Reconciled Depreciation | 0.37 | 0.15 | 0.09 | 0.10 |
| Net Interest Income | 0.65 | 1.58 | 1.82 | 2.50 |
| Net Income From Continuing And Discontinued Operation | -41.31 | -27.03 | -62.29 | -15.28 |
| Total Operating Income As Reported | -32.56 | -23.41 | -27.55 | -42.97 |
| Diluted Average Shares | 46.55 | 48.03 | 60.99 | 0 |
| Basic Average Shares | 46.55 | 48.03 | 60.99 | 0 |
| Diluted NI Availto Com Stockholders | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income Including Noncontrolling Interests | -41.31 | -27.03 | -62.29 | -15.28 |
| Net Income Continuous Operations | -41.31 | -27.03 | -62.29 | -15.28 |
| Other Income Expense | -9.40 | -5.21 | -36.57 | 25.18 |
| Other Non Operating Income Expenses | 0.59 | 0.08 | 0 | 0 |
| Special Income Charges | 0.02 | 0 | 0.01 | 0 |
| Gain On Sale Of Ppe | 0.02 | 0 | 0.01 | 0 |
| Earnings From Equity Interest | -10.01 | -5.28 | -3.20 | -1.96 |
| Gain On Sale Of Security | 0 | 0 | -33.38 | 27.14 |
| Net Non Operating Interest Income Expense | 0.65 | 1.58 | 1.82 | 2.50 |
| Total Other Finance Cost | -0.65 | -1.58 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.65 | 1.58 | 1.82 | 2.50 |
| General And Administrative Expense | 8.10 | 6.88 | 8.16 | 9.25 |
| Other Gand A | 8.10 | 6.88 | 8.16 | 9.25 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc.this co. | CRVS | $1.2B | - | 17.61 | -25.0% | -26.95 |
| Novavax, Inc. | NVAX | $1.3B | 3.09 | -10.14 | -344.7% | 1.42 |
| Butterfly Network, Inc. | BFLY | $1.3B | - | 6.37 | -39.3% | -20.73 |
| MapLight Therapeutics, Inc. | MPLT | $1.3B | - | 2.91 | -35.2% | -6.14 |
| PROCEPT BioRobotics Corporation | PRCT | $1.2B |
| - |
| 3.34 |
| -26.1% |
| -10.43 |
| Olema Pharmaceuticals, Inc. | OLMA | $1.2B | - | 2.40 | -33.9% | -4.35 |
| CONMED Corporation | CNMD | $1.2B | 25.12 | 1.14 | 4.6% | 11.20 |
| Kestra Medical Technologies, Ltd. | KMTS | $1.1B | - | 3.95 | -55.4% | -6.60 |
| UroGen Pharma Ltd. | URGN | $1.1B | - | -10.70 | 145.5% | -9.20 |
| Peer Median | - | 14.11 | 2.66 | -34.6% | -6.37 | |